Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	-
Bid (Size)	172.36 (11)
Ask (Size)	172.50 (475)
Prev. Close	172.36
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	36,948,063
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗

December 29, 2023

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.

Via Benzinga

An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8 ↗

October 05, 2023

Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attention to gold miners”:

Via Benzinga

Performance

More News

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shareholder Notice: Investigation over Potential Wrongdoing ↗

October 04, 2023

Via SBWire

Biogen Completes Acquisition of Reata Pharmaceuticals

September 26, 2023

From Biogen Inc.

Via GlobeNewswire

Analyst Ratings for Reata Pharmaceuticals ↗

August 15, 2023

Via Benzinga

Reata Pharmaceuticals Inc. (NASDAQ: RETA) Climbs to New 52-Week High

September 21, 2023

Via Investor Brand Network

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

September 21, 2023

From Reata Pharmaceuticals, Inc.

Via Business Wire

Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy? ↗

September 09, 2023

Via The Motley Fool

7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth ↗

September 07, 2023

Via InvestorPlace

The 7 Most Promising Momentum Stocks to Own Now ↗

August 31, 2023

Via InvestorPlace

The 3 Most Promising Pharma Stocks to Own Now ↗

August 30, 2023

Via InvestorPlace

REATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA

August 28, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Earthstone Energy, Inc. (NYSE - ESTE), Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)

August 21, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)

August 17, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 14, 2023

Via Benzinga

With an Acquisition on the Way, Is Biogen Stock a Buy? ↗

August 09, 2023

Via The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)

August 08, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 08, 2023

Via Benzinga

August 07, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

REATA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA

August 02, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points ↗

August 01, 2023

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2023 ↗

August 01, 2023

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Talaris Therapeutics, Inc. (Nasdaq - TALS), Inpixon® (Nasdaq - INPX)

August 01, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know. ↗

August 01, 2023

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗

July 31, 2023

Via Benzinga

Frequently Asked Questions

Is Reata Pharmaceuticals, Inc. - Class A Common Stock publicly traded?

Yes, Reata Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.

What exchange does Reata Pharmaceuticals, Inc. - Class A Common Stock trade on?

Reata Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Reata Pharmaceuticals, Inc. - Class A Common Stock?

The ticker symbol for Reata Pharmaceuticals, Inc. - Class A Common Stock is RETA on the Nasdaq Stock Market

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.